Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EGFR inhibitor

- PMLiVE

Another NICE rejection for Roche’s Avastin

Second draft guidance turns down drug’s use in advanced ovarian cancer

PatientsLikeMe launches clinical trial search tool for patients

Online community wants to match patients to suitable studies

- PMLiVE

Dismay as NICE turns down Afinitor for breast cancer

Patient groups say draft guidance is a major blow to women in England and Wales

- PMLiVE

Novartis turns from social networking to apps for trial recruitment

Launches iPhone and Android cancer trial app in the US

Novartis building

FDA deems Novartis lung cancer drug a “breakthrough therapy”

LDK378 will have accelerated passage through development

- PMLiVE

Informatics to drive clinical trials in UK

Scotland’s chief scientist says NHS data can support medicines research

- PMLiVE

Roche chairman Franz Humer to step down

Will not stand for re-election in 2014

- PMLiVE

Bayer fails to overturn Nexavar compulsory licence in India

Natco Pharma allowed to sell cut-price version of cancer drug

- PMLiVE

Roche gains EU approval for Perjeta in breast cancer

Available in combination with Herceptin and docetaxel chemotherapy

- PMLiVE

Novartis provides multimedia support to Rare Diseases Day

Collaborates with Eurordis on multimedia education campaign

Roche - Basel

Roche promises greater access to clinical trial data

Company critics say measures do not go far enough

Roche - Basel

Roche’s Herceptin follow-up cleared in US

FDA approval for Kadcyla (formerly T-DM1) in breast cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links